当前位置: Nature » 免疫学 » 正文


摘要 : 2016年6月3日,国际学术权威刊物自然出版集团旗下子刊《Nature Reviews Cancer》在线发表了美国哈佛大学医学院卢坤平教授的一篇癌症综述文章,文章指出异构酶PIN1控制着多个癌症驱动通路,是一个独特的抗癌靶标。

 2016年6月3日,国际学术权威刊物自然出版集团旗下子刊《Nature Reviews Cancer》在线发表了美国哈佛大学医学院卢坤平教授的一篇癌症综述文章,文章指出异构酶PIN1控制着多个癌症驱动通路,是一个独特的抗癌靶标。




The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target


Targeted drugs have changed cancer treatment but are often ineffective in the long term against solid tumours, largely because of the activation of heterogeneous oncogenic pathways. A central common signalling mechanism in many of these pathways is proline-directed phosphorylation, which is regulated by many kinases and phosphatases. The structure and function of these phosphorylated proteins are further controlled by a single proline isomerase: PIN1. PIN1 is overactivated in cancers and it promotes cancer and cancer stem cells by disrupting the balance of oncogenes and tumour suppressors. This Review discusses the roles of PIN1 in cancer and the potential of PIN1 inhibitors to restore this balance.

来源: Nature Reviews Cancer 浏览次数:0


RSS订阅 - 填写您的邮件地址,订阅我们的精彩内容: - 网站地图
网站联系电话:020-87540820 备案号:粤ICP备11050685号-8 增值电信业务经营许可证:粤B2-20120479
©2011-2015 生物帮 All rights reserved.